Shweta Baral: Clinical Outcomes and Safety of Low-Dose Nivolumab in Palliative Head and Neck Cancer
Shweta Baral/kccrc.org

Shweta Baral: Clinical Outcomes and Safety of Low-Dose Nivolumab in Palliative Head and Neck Cancer

Shweta Baral, Radiation Oncologist at Bhaktapur Cancer Hospital in Kathmandu, Nepal, shared insights from a retrospective audit evaluating the efficacy, safety, and cost-effectiveness of ultra-low-dose nivolumab in 71 patients with palliative head and neck cancer, highlighting its potential to make immunotherapy more accessible in resource-limited settings:

“Core Context and Rationale In Nepal, head and neck cancer (HNC) carries a heavy burden, with most patients presenting at locally advanced or metastatic stages requiring palliative care. While standard-dose nivolumab (240 mg every 2 weeks) is effective, its cost (~USD 1,658 per dose) exceeds Nepal’s annual per capita income (~USD 1,536), putting it out of reach for nearly all patients.

Drawing on pharmacokinetic evidence that much lower doses can saturate PD-1 receptors, the authors evaluated an ultra-low-dose regimen of nivolumab (20 mg every 3 weeks) – achieved by splitting a 40 mg vial across cycles – with or without modified oral metronomic chemotherapy (gefitinib and weekly methotrexate) in 71 palliative HNC patients at Bhaktapur Cancer Hospital.

Key Findings

Clinical Efficacy
  • The regimen yielded an encouraging overall response rate (ORR) of 53.51%, including a 15.49% complete response (CR) rate (11 patients) and a 38.02% partial response (PR) rate. Notably, six patients – predominantly elderly individuals over 75 – achieved a CR using single-agent low-dose nivolumab.
Survival and Palliation
  • Patients achieving a CR experienced a 1-year overall survival of 81.8% (compared to 33.3% for PR). Beyond tumor shrinkage, patients reported meaningful reductions in baseline pain, fatigue, anorexia, and nausea.
Safety and Cost
  • The regimen reduced 3-month drug costs by roughly 18-fold compared to standard dosing, bringing expenses in line with conventional palliative chemotherapy and government insurance coverage. Additionally, the costs of supportive care like hospital admission, multiple blood tests, and filgrastim could be avoided with  low  dose Nivolumab which reduced the overall cost of treatment. Toxicity was manageable without treatment discontinuations due to immune-related adverse events, though hypothyroidism (49.29%) and dermatitis (~50%) were common.
Strengths and Limitations
  • The study’s primary strength lies in its pragmatic, resource-adapted design – demonstrating how vial-sharing and locally available metronomic substitutes (gefitinib instead of erlotinib) can deliver life-extending immunotherapy in a public cancer center. However, as a single-center retrospective audit with a heterogeneous patient cohort (varying prior chemoradiation and concurrent metronomic therapy) and no PD-L1 biomarker testing, the independent efficacy of low-dose nivolumab cannot be isolated. Furthermore, survival comparisons across response groups are subject to guarantee-time bias due to the lack of a landmark analysis.”

Title: Outcomes and safety of low dose nivolumab in patients with palliative head and neck cancer: A retrospective audit from Nepal

Authors: Shweta Baral, Sudhir Raj Silwal, Bibek Khanal, Archana Amatya, Suraj Suwal, Deep Lamichhane

Read the Full Article.

You can also read: NIVOTAX Trial: Paclitaxel Plus Nivolumab in Cisplatin-Ineligible Head and Neck Cancer

Shweta Baral: Clinical Outcomes and Safety of Low-Dose Nivolumab in Palliative Head and Neck Cancer